Patient Philosophy

Liana, diagnosed with hATTR amyloidosis
and her daughter Gabriella (Brazil)

Our Patient Access Philosophy & Progress
Fact Sheet

Download our 2023 Patient Access Philosophy Fact Sheet to see statistics that illustrate our progress against these principles.


patients on our commercial therapies worldwide

U.S. residents with confirmed access to one of our therapies

countries where patients can access our therapies by way of direct or distributor infrastructure

Alnylam’s Patient Access Philosophy Principles

Sustainable Value and Significant Impact

We believe it is our responsibility to push the boundaries of scientific discovery, clinical development, and delivery to fuel significant, sustainable patient impact.


  • We make decisions for as many people who can benefit from the potential of our medicines.
  • We believe we have an obligation to commit resources that promote diversity of clinical trials, ensure equitable access, and empower individuals with choice.
  • We act with purposeful urgency to expand our geographic reach and enable sustainable access pathways.

Connecting to Achieve Better Outcomes

We believe that together with partners in the healthcare ecosystem, we can reduce barriers to our medicines to improve outcomes for all stakeholders in the patient journey – most importantly, for the patients who may benefit from them.


  • We believe biopharmaceutical companies must address access and improve outcomes from the time of drug discovery.
  • We recognize that a patient’s ability to access and afford our medicines is complex, and we commit to continuing our legacy of value-centric solutions.
  • We seek to remove barriers within our control to enable patients to receive care in convenient settings.

Proactive and Accountable

We believe that biopharmaceutical companies play a critical role in the patient’s journey to accessing innovative therapeutic options and should be accountable for progress.


  • We aim to create compliant solutions that are designed to empower patients to feel confident throughout their treatment journey.
  • We advocate for policies, technology and evidence to promote innovation and reduce the time for approved treatments to reach patients.
  • We partner with others for the sake of science and the good of patients, committed to the continuous evolution that began before we launched the world’s first RNAi therapeutic and will endure for as long as we are Alnylam.

Learn More About How We Measure Our Progress Against Our Patient Access Philosophy Principles:


2023 Approach to Access and Affordability Fact Sheet


Corporate Social Responsibility Report 2023


Additional Information

Alnylam Assist®

Alnylam Assist®

Alnylam Assist® offers you a number of personalized services throughout your treatment with an Alnylam product.


Alnylam Act®

Alnylam Act® provides no-charge, independent genetic testing and counseling to individuals in the U.S. and Canada who may have hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1.



Receive news and updates on the work at Alnylam that affects you most.
Custom Body Class